This activity was originally presented live at Asembia's AXS26 Summit in Las Vegas, Nevada
Program Description
Transthyretin amyloidosis cardiomyopathy
(ATTR-CM) is an underrecognized, progressive, and fatal condition characterized
by the systemic deposition of misfolded transthyretin protein in the
myocardium. For years, treatment options were limited to supportive care,
leaving patients to face a heavy burden of cardiovascular morbidity and a
steady decline in functional independence. Modern management, however, has
transitioned toward disease-modifying therapies, yet significant challenges
remain regarding high therapy costs, complex specialty pharmacy workflows, and
the clinical difficulty of early recognition of ATTR-CM. The therapeutic
landscape is now expanding further with emerging gene-silencing strategies,
which offer the advantage of potent TTR reduction and subcutaneous dosing.
These advancements necessitate that specialty and managed care pharmacists are
equipped to navigate evolving evidence on treatment sequencing, combination
strategies, and the interpretation of biomarkers like serum TTR. This session
features an expert-led discussion of the latest clinical guidelines and
real-world evidence to support individualized treatment planning for patients
with ATTR-CM. Faculty experts will examine the critical role of specialty and
managed care pharmacists in orchestrating multidisciplinary care, from
streamlining diagnostic pathways and managing complex distribution processes to
implementing evidence-based protocols that ensure long-term adherence and
improved quality of life for patients with ATTR-CM.
Target audience: Managed
Care Pharmacist, Specialty Pharmacist
Type of activity: Application
Release date: May 11, 2026
Expiration date: May 11, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the burden of transthyretin amyloidosis cardiomyopathy (ATTR-CM), including misdiagnosis, quality-of-life impact, and drivers of health care utilization
- Interpret current treatment recommendations for ATTR-CM, incorporating mechanisms of action, dosing, administration, and safety considerations for approved and emerging therapies
- Apply available clinical evidence for approved and investigational ATTR-CM therapies to support individualized treatment planning
- Exercise strategies to reduce care burden and improve access, leveraging multidisciplinary coordination to optimize therapy initiation and ongoing management in ATTR-CM